View Item 

Show simple item record

Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy

dc.contributor.authorMarcath, Lauren A.
dc.contributor.authorKidwell, Kelley M.
dc.contributor.authorVangipuram, Kiran
dc.contributor.authorGersch, Christina L.
dc.contributor.authorRae, James M.
dc.contributor.authorBurness, Monika L.
dc.contributor.authorGriggs, Jennifer J.
dc.contributor.authorVan Poznak, Catherine
dc.contributor.authorHayes, Daniel F.
dc.contributor.authorSmith, Ellen M. Lavoie
dc.contributor.authorHenry, N. Lynn
dc.contributor.authorBeutler, Andreas S.
dc.contributor.authorHertz, Daniel L.
dc.date.accessioned2020-05-05T19:36:24Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-05-05T19:36:24Z
dc.date.issued2020-05
dc.identifier.citationMarcath, Lauren A.; Kidwell, Kelley M.; Vangipuram, Kiran; Gersch, Christina L.; Rae, James M.; Burness, Monika L.; Griggs, Jennifer J.; Van Poznak, Catherine; Hayes, Daniel F.; Smith, Ellen M. Lavoie; Henry, N. Lynn; Beutler, Andreas S.; Hertz, Daniel L. (2020). "Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy." British Journal of Clinical Pharmacology 86(5): 880-890.
dc.identifier.issn0306-5251
dc.identifier.issn1365-2125
dc.identifier.urihttps://hdl.handle.net/2027.42/154957
dc.publisherWiley Periodicals, Inc.
dc.publisherBrussels
dc.subject.otherpharmacodynamics
dc.subject.otherpharmacogenomics
dc.subject.otherpharmacokinetics
dc.subject.othergenetic polymorphism
dc.subject.otherbreast cancer
dc.titleGenetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154957/1/bcp14192.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154957/2/bcp14192_am.pdf
dc.identifier.doi10.1111/bcp.14192
dc.identifier.sourceBritish Journal of Clinical Pharmacology
dc.identifier.citedreferenceFayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ‐C30 Scoring Manual. 3rd Editon. European Organisation for Research and Treatment of Cancer: Brussels; 2001.
dc.identifier.citedreferenceJoerger M, von Pawel J, Kraff S, et al. Open‐label, randomized study of individualized, pharmacokinetically (PK)‐guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non‐small‐cell lung cancer (NSCLC). Ann Oncol. 2016; 27: 1895 ‐ 1902.
dc.identifier.citedreferenceHertz DL, Kidwell KM, Vangipuram K, et al. Paclitaxel plasma concentration after the first infusion predicts treatment‐limiting peripheral neuropathy. Clin Cancer Res. 2018; 24 ( 15 ): 3602 ‐ 3610.
dc.identifier.citedreferenceBaldwin RM, Owzar K, Zembutsu H, et al. A genome‐wide association study identifies novel loci for paclitaxel‐induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012; 18 ( 18 ): 5099 ‐ 5109.
dc.identifier.citedreferenceSucheston‐Campbell LE, Clay‐Gilmour AI, Barlow WE, et al. Genome‐wide meta‐analyses identifies novel taxane‐induced peripheral neuropathy‐associated loci. Pharmacogenet Genomics. 2018; 28: 49 ‐ 55.
dc.identifier.citedreferenceSchneider BP, Lai D, Shen F, et al. Charcot‐Marie‐tooth gene, SBF2, associated with taxane‐induced peripheral neuropathy in African Americans. Oncotarget. 2016; 7 ( 50 ): 82244 ‐ 82253.
dc.identifier.citedreferenceAbraham JE, Guo Q, Dorling L, et al. Replication of genetic polymorphisms reported to be associated with taxane‐related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res. 2014; 20: 2466 ‐ 2475.
dc.identifier.citedreferenceBoora GK, Kanwar R, Kulkarni AA, et al. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med. 2016; 5 ( 4 ): 631 ‐ 639.
dc.identifier.citedreferenceApellaniz‐Ruiz M, Tejero H, Inglada‐Perez L, et al. Targeted sequencing reveals low‐frequency variants in EPHA genes as markers of paclitaxel‐induced peripheral neuropathy. Clin Cancer Res. 2017; 23: 1227 ‐ 1235.
dc.identifier.citedreferenceSchneider BP, Li L, Radovich M, et al. Genome‐wide association studies for Taxane‐induced peripheral neuropathy in ECOG‐5103 and ECOG‐1199. Clin Cancer Res. 2015; 21 ( 22 ): 5082 ‐ 5091.
dc.identifier.citedreferenceLeandro‐Garcia LJ, Inglada‐Perez L, Pita G, et al. Genome‐wide association study identifies ephrin type a receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013; 50 ( 9 ): 599 ‐ 605.
dc.identifier.citedreferenceLam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel‐treated breast cancer patients. Br J Cancer. 2016; 115 ( 11 ): 1335 ‐ 1342.
dc.identifier.citedreferenceFlanagan JG, Vanderhaeghen P. The ephrins and Eph receptors in neural development. Annu Rev Neurosci. 1998; 21: 309 ‐ 345.
dc.identifier.citedreferenceApellaniz‐Ruiz M, Sanchez‐Barroso L, Gutierrez‐Gutierrez G, et al. Replication of genetic polymorphisms reported to be associated with Taxane‐related sensory neuropathy in patients with early breast cancer treated with paclitaxel‐‐letter. Clin Cancer Res. 2015; 21: 3092 ‐ 3093.
dc.identifier.citedreferenceMehrotra S, Sharma MR, Gray E, et al. Kinetic‐Pharmacodynamic model of chemotherapy‐induced peripheral neuropathy in patients with metastatic breast cancer treated with paclitaxel, nab‐paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS j. 2017; 19 ( 5 ): 1411 ‐ 1423.
dc.identifier.citedreferenceJoerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res. 2006; 12 ( 7 Pt 1 ): 2150 ‐ 2157.
dc.identifier.citedreferenceKraff S, Lindauer A, Joerger M, Salamone SJ, Jaehde U. Excel‐based tool for Pharmacokinetically guided dose adjustment of paclitaxel. Ther Drug Monit. 2015; 37 ( 6 ): 725 ‐ 732.
dc.identifier.citedreferenceLavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient‐reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of cancer QLQ‐CIPN20 questionnaire. Qual Life Res. 2013; 22 ( 10 ): 2787 ‐ 2799.
dc.identifier.citedreferenceKieffer JM, Postma TJ, van de Poll‐Franse L, et al. Evaluation of the psychometric properties of the EORTC chemotherapy‐induced peripheral neuropathy questionnaire (QLQ‐CIPN20). Qual Life Res. 2017; 26: 2999 ‐ 3010.
dc.identifier.citedreferenceBeutler AS, Kulkarni AA, Kanwar R, et al. Sequencing of Charcot‐Marie‐tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014; 76 ( 5 ): 727 ‐ 737.
dc.identifier.citedreferenceSikora MJ, Thibert JN, Salter J, Dowsett M, Johnson MD, Rae JM. High‐efficiency genotype analysis from formalin‐fixed, paraffin‐embedded tumor tissues. Pharmacogenomics J. 2011; 11: 348 ‐ 358.
dc.identifier.citedreferenceKircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014; 46 ( 3 ): 310 ‐ 315.
dc.identifier.citedreferenceRentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019; 47: D886 ‐ D894.
dc.identifier.citedreferenceChoi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012; 7: 1 ‐ 12, e46688.
dc.identifier.citedreferenceWard LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012; 40: D930 ‐ D934.
dc.identifier.citedreferenceConsortium GT. The genotype‐tissue expression (GTEx) project. Nat Genet. 2013; 45: 580 ‐ 585.
dc.identifier.citedreferenceGewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy‐induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018; 91 ( 9 ): 403 ‐ 413.
dc.identifier.citedreferenceHertz DL. Concerns regarding use of patient reported outcomes in biomarker studies of chemotherapy‐induced peripheral neuropathy. Pharmacogenomics J. 2019; 19: 411 ‐ 416.
dc.identifier.citedreferenceDrubay D, Gautheret D, Michiels S. A benchmark study of scoring methods for non‐coding mutations. Bioinformatics. 2018; 34 ( 10 ): 1635 ‐ 1641.
dc.identifier.citedreferenceShihab HA, Rogers MF, Gough J, et al. An integrative approach to predicting the functional effects of non‐coding and coding sequence variation. Bioinformatics. 2015; 31 ( 10 ): 1536 ‐ 1543.
dc.identifier.citedreferenceHassan MS, Shaalan AA, Dessouky MI, Abdelnaiem AE, ElHefnawi M. Evaluation of computational techniques for predicting non‐synonymous single nucleotide variants pathogenicity. Genomics. 2019; 111: 869 ‐ 882.
dc.identifier.citedreferenceLi MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017; 19 ( 1 ): 4 ‐ 23.
dc.identifier.citedreferencePerez EA. Paclitaxel in breast cancer. Oncologist. 1998; 3 ( 6 ): 373 ‐ 389.
dc.identifier.citedreferenceBudd GT, Barlow WE, Moore HC, et al. SWOG S0221: a phase III trial comparing chemotherapy schedules in high‐risk early‐stage breast cancer. J Clin Oncol. 2015; 33 ( 1 ): 58 ‐ 64.
dc.identifier.citedreferenceSparano JA, Zhao F, Martino S, et al. Long‐term follow‐up of the E1199 phase III trial evaluating the role of Taxane and schedule in operable breast cancer. J Clin Oncol. 2015; 33 ( 21 ): 2353 ‐ 2360.
dc.identifier.citedreferenceMols F, Beijers T, Vreugdenhil G, van de Poll‐Franse L. Chemotherapy‐induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014; 22 ( 8 ): 2261 ‐ 2269.
dc.identifier.citedreferenceSpeck RM, Sammel MD, Farrar JT, et al. Impact of chemotherapy‐induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013; 9: e234 ‐ e240.
dc.identifier.citedreferenceLoibl S, Skacel T, Nekljudova V, et al. Evaluating the impact of relative Total dose intensity (RTDI) on patients’ short and long‐term outcome in taxane‐ and anthracycline‐based chemotherapy of metastatic breast cancer‐ a pooled analysis. BMC Cancer. 2011; 11: 1 ‐ 8, 131.
dc.identifier.citedreferenceZhang L, Yu Q, Wu XC, et al. Impact of chemotherapy relative dose intensity on cause‐specific and overall survival for stage I‐III breast cancer: ER+/PR+, HER2‐ vs. triple‐negative. Breast Cancer Res Treat. 2018; 169 ( 1 ): 175 ‐ 187.
dc.identifier.citedreferencede Graan AJ, Elens L, Sprowl JA, et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel‐induced neurotoxicity. Clin Cancer Res. 2013; 19 ( 12 ): 3316 ‐ 3324.
dc.identifier.citedreferenceMielke S, Sparreboom A, Steinberg SM, et al. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005; 11 ( 13 ): 4843 ‐ 4850.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bcp14192.pdf
Size:
1000.KB
Format:
PDF
View/Open
Name:
bcp14192_am.pdf
Size:
624.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.